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Abstract
Chronic inflammation is involved in the pathogenesis of obesity and type 2 diabetes. Recently, teasaponin, an
extract from tea, has been shown to have anti-inflammatory effects. We examined the effect of teasaponin on
obesity, inflammation, glucose metabolism and central leptin sensitivity, in obese mice fed a high-fat (HF)
diet for 16 weeks. Intraperitoneal injections of teasaponin (10mg/kg, daily) for 21 days significantly decreased
the food intake and body weight of HF diet-induced obese mice. Teasaponin treatment also reduced the
protein levels of pro-inflammatory cytokines (TNF-α, IL-6 and/or IL-1β) and NF-κB signaling (p-IKK and p-
IκBα) in adipose tissue and the liver. The anti-inflammatory effects of teasaponin were associated with
improved glycemic status in the treated animals, evidenced by improved glucose tolerance, homeostasis
model assessment (HOMA) and fasting plasma insulin. In the hypothalamus teasaponin decreased both pro-
inflammatory cytokines and inflammatory signaling in the mediobasal hypothalamus. Teasaponin treatment
also enhanced the anorexigenic effect of central leptin administration, restored leptin p-STAT3 signaling in
the Arc, and increased hypothalamic expression of the anorexigenic peptide proopiomelanocortin (POMC).
These results identify a potential novel application for teasaponin as an anti-obesity and anti-inflammatory
agent.
Keywords
obese, induced, diet, resistance, leptin, central, mice, inflammation, male, reduces, teasaponin
Disciplines
Medicine and Health Sciences
Publication Details
Yu, Y., Wu, Y., Szabo, A., Wu, Z., Wang, H., Li, D. & Huang, X. (2013). Teasaponin reduces inflammation and
central leptin resistance in diet-induced obese male mice. Endocrinology, 154 (9), 3130-3140.
Authors
Yinghua Yu, Yizhen Wu, Alexander Szabo, Zhixiang Wu, Hongqin Wang, Duo Li, and Xu-Feng Huang
This journal article is available at Research Online: http://ro.uow.edu.au/ihmri/353
Teasaponin reduces inflammation and central leptin
resistance in diet-induced obese male mice
Yinghua Yu1,2, Yizhen Wu1, Alexander Szabo1,3, Zhixiang Wu1,4,
Hongqin Wang1, Duo Li2, Xu-Feng Huang1,*
1. Illawarra Health and Medical Research Institute, School of Health Sciences, University of Wollongong,
Wollongong, NSW, 2522, Australia; 2. Department of Food Science and Nutrition, Zhejiang University,
866 Yu-Hang-Tang Rd, Hangzhou 310058, China; 3. ANSTO LifeSciences, Australian Nuclear Science
and Technology Organisation (ANSTO), Lucas Heights, NSW, 2234, Australia; 4. Department of
Endocrinology and Metabolism, Affiliated Hospital of Liaoning University of Traditional Chinese
Medicine, China
Chronic inflammation is involved in the pathogenesis of obesity and type 2 diabetes. Recently,
teasaponin, an extract from tea, has been shown to have anti-inflammatory effects. We examined
the effect of teasaponin on obesity, inflammation, glucose metabolism and central leptin sensi-
tivity, in obese mice fed a high-fat (HF) diet for 16 weeks. Intraperitoneal injections of teasaponin
(10mg/kg, daily) for 21 days significantly decreased the food intake and body weight of HF diet-
induced obese mice. Teasaponin treatment also reduced the protein levels of pro-inflammatory
cytokines (TNF-, IL-6 and/or IL-1) and NF-B signaling (p-IKK and p-IB) in adipose tissue and the
liver. The anti-inflammatory effects of teasaponin were associated with improved glycemic status
in the treated animals, evidenced by improved glucose tolerance, homeostasis model assessment
(HOMA) and fasting plasma insulin. In the hypothalamus teasaponin decreased both pro-inflam-
matory cytokines and inflammatory signaling in the mediobasal hypothalamus. Teasaponin treat-
ment also enhanced the anorexigenic effect of central leptin administration, restored leptin p-
STAT3 signaling in the Arc, and increased hypothalamic expression of the anorexigenic peptide
proopiomelanocortin (POMC). These results identify a potential novel application for teasaponin
as an anti-obesity and anti-inflammatory agent.
Obesity has reached epidemic proportions and is animportant risk factor for the development of type 2
diabetes, cardiovascular disease, and some forms of can-
cer. There is compelling evidence that a large component
of obesity-associated pathophysiology may stem from the
low-grade inflammation that occurs during obesity. This
includes increased production of proinflammatory cyto-
kines such as tumor necrosis factor (TNF) alpha (TNF-),
interleukin 1 beta (IL-1) and interleukin 6 (IL-6), and
activation of the nuclear factor -light-chain-enhancer of
activated B cells (NF-B) inflammatory signaling pathway
in adipose tissue, liver and the hypothalamus of the brain
(1, 2).
Overnutrition induces inflammatory responses in pe-
ripheral metabolic tissues, including the infiltration of
proinflammatory cytokine secreting macrophages into the
adipose tissue of obese mice and humans (1, 3, 4). Proin-
flammatory cytokines decrease insulin sensitivity in insu-
lin target cells (adipocytes, hepatocytes and myocytes) and
contribute to systemic insulin resistance, glucose intoler-
ance and the development of type 2 diabetes. In obese
rodents fed a high-fat (HF) diet, macrophages also infil-
trate the liver and increase the mRNA expression of the
proinflammatory cytokines TNF-, IL-1 and IL-6 (5, 6).
Inflammatory cytokines released by liver macrophages
can activate the NF-B signaling pathway in hepatocytes,
causing hepatic insulin resistance (1, 6). Recent research
has identified a similar type of low-grade inflammation in
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the hypothalamus of rodents (2), where TNF-, IL-6 and
IB kinase (IKK) mRNA expression are increased within
a week of starting a HF diet. IKK along with inhibitor
kappa B alpha (IB) are components of the NF-B sig-
naling pathway, and commonly used to investigate in-
flammatory signaling events. Hypothalamic inflamma-
tion results in central leptin resistance, hepatic insulin
resistance, a reduction in thermogenesis and cardiovascu-
lar disorders (7). Therefore, blocking the peripheral and
central inflammation induced by HF diet has the potential
to treat obesity and metabolic syndrome. This could be
achieved using novel therapies incorporating effective nat-
ural agents, particularly agents with the dual properties of
preventing inflammation and controlling body weight.
From ancient times tea has been widely used as a
healthy drink worldwide. Recent evidence has emerged
that tea can prevent obesity and abnormal glucose and
lipid metabolism (8, 9). The earliest use of tea for medic-
inal purposes occurred in China, in roughly 2700 BC dur-
ing the time of Emperor Shen Nung (10). During that time,
it was believed to have health promoting properties, and
was frequently used as a fluid supply for patients with
infectious diseases. Recently, the effect of tea on inflam-
mation has received increasing attention. Six cups of green
tea daily for three to eight weeks significantly reduced
NF-B signaling in men with prostate cancer prior to un-
dergoing prostatectomy, compared to the control group
(11). Treatment of genetically obese (ob/ob) mice with 1%
tea extract in diet for 6 wk decreased hepatic TNF- pro-
tein, adipose TNF- mRNA, and attenuated hepatic ste-
atosis (12). Furthermore, supplementation of HF diet with
tea extract significantly reduced HF diet induced p-IB
and NF-B activity in liver and adipose tissue (13). Phe-
nolics and saponin are the two major active components
of tea extract. Phenolics in tea have been widely investi-
gated in previous studies, while teasaponin (TS), an im-
portant bioactive ingredient of tea extract, has received
little attention. Teasaponin chemically, belongs to the
oleanane-type pentacyclic triterpene saponins, which are
naturally derived inhibitors of NF-kB signaling and have
anti-inflammatory potential (14). Recently teasaponin (10
mg/kg ip injection) showed significant anti-inflammatory
properties, by inhibiting paw edema induced by car-
rangeenan in rats (15). In this study, we investigated
whether chronic treatment with teasaponin could reduce
inflammation in the hypothalamus and peripheral tissues,
and therefore improve blood glucose control and central
leptin sensitivity in HF diet-induced obese mice.
Materials and Methods
Animals
Animals: C57Bl/6J male mice (10 wk old, body weight:
19.62  1.40g) were obtained from the Animal Resources Cen-
tre (Perth, Western Australia). The mice were housed in envi-
ronmentally controlled conditions (temperature 22°C, 12 h
light/dark cycle). Lab chow served as the low-fat (LF) control diet
(5% fat, Vella Stock Feeds, Doonside, NSW, Australia) and was
provided ad libitum except where noted. All procedures were
approved by the Animal Ethics Committee, University of Wol-
longong, Australia, and complied with the Australian Code of
Practice for the Care and Use of Animals for Scientific Purposes.
Teasaponin treatment of high-fat diet-induced
obese mice
Mice were fed standard laboratory chow for the first week to
allow them to adapt to their new environment, and then placed
on a high-fat (HF) diet containing 40% fat by calories (SF11–
095; Specialty Feeds, Western Australia) for 16 wk. After this
feeding period the mice were obese (mean body weight 44.18 
2.60g). The animals were then randomized into two groups, with
either teasaponin (TS, 10 mg/kg) or vehicle (saline) administered
daily via intraperitoneal (ip) injection for 21 d (chronic treatment
of teasaponin). Food intake and body weight were recorded
daily. Also included in this study were low-fat (LF) diet control
mice, which were age-matched, maintained on the LF control
diet, and not treated with TS. Teasaponin (96%, C57H90O26,
MW  1200) was purchased from the Aladdin Chemistry Co.
Ltd, China.
Blood glucose tolerance tests were performed on day 18 of
teasaponin treatment. The cannula implantation surgery was
performed following 21 d of TS treatment. After a 5 d recovery
from surgery, the first icv administration of leptin (or saline) was
performed for the central leptin sensitivity test (detailed below).
Following a 4 d interval, the mice received the second icv leptin
injection and were sacrificed one hour later to collect tissues as
in the previous study (16). Plasma, white adipose tissue, liver and
brain tissue were collected and stored at –80°C for further anal-
yses as detailed below.
Similar to the previous study (17), the frozen brain sections
containing the arcuate nucleus were cut at 500 m ranging from
Bregma –1.22 mm to –2.72 mm based on a standard mouse brain
atlas (18), using a cryostat with the temperature set at –18°C. The
arcuate nucleus was dissected and then collected using a Stoelting
Brain Punch (#57401, 0.5 mm diameter, Wood Dale, Stoelting
Co, USA) in an overlapping pattern over the third ventricle. The
punched tissue principally contained arcuate nucleus, but we
cannot rule out the inclusion of adjacent brain areas. Therefore,
the punched tissue was named as the mediobasal hypothalamus.
Intraperitoneal glucose tolerance test
On day 18 of the teasaponin treatment, the mice fasted over-
night and were given an ip injection of glucose (0.5g/kg). Blood
samples were taken from the tail vein, and glucose was measured
using a glucometer (Freestyle; Abbott Diabetes Care, Alameda,
CA) at 0 (fasting), 30, 60 and 120 min after glucose
administration.
Central leptin sensitivity tests
The central leptin sensitivity was examined in moderate and
severely obese mice. For moderate obesity, mice were fed a high-
fat diet for 8 wk followed by an acute treatment of teasaponin (10
mg/kg/day, ip) for 2 d. For severe obesity, the mice were fed a
high-fat diet for 16 wk followed by a chronic treatment of teasa-
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ponin (10 mg/kg/day, ip) for 21 d. Animals were maintained on
a high-fat diet during both acute and chronic teasaponin treat-
ment. The central leptin sensitivity test was performed as fol-
lows. Mice were anesthetized by isoflurane inhalation and placed
in a stereotactic device. An intracerebroventricular (icv) cannula
was implanted into the right lateral brain ventricle (0.25 mm
posterior and 1.0 mm lateral relative to Bregma and 2.5 mm
below the surface of the skull) (18). Five days after implantation,
the mice fasted for 6 h. Either leptin (0.1 g/3 l) or saline (3 l)
was then injected into the lateral ventricle through the cannula.
Food intake was measured at 1, 4 and 24 h, and body weight was
measured 24 h after the leptin or vehicle injection. The accuracy
of cannula implantation into the lateral ventricle was confirmed
by examining the needle track on the brain sections of each
animal.
Conditioned taste aversion
We used a standard two-bottle preference paradigm (19, 20).
Mice were adapted to 2 h daily access to water (available in two
bottles) for 10 d. On day 11, the mice were given 0.15% sac-
charin in water in each bottle for the 2 h period instead of water,
and then injected with either teasaponin (10 mg/kg, ip), vehicle
(saline 0.3 ml, ip), or LiCl as a positive control (0.15 mol/l; 2
mmol/kg ip) (n  8). On days 12–13, the animals had water in
both bottles, and on the test day (day 14), the mice were given one
bottle containing saccharin and one containing water. The sac-
charin preference ratio was calculated as the amount of saccharin
consumed divided by the total consumption of both liquids over
2 h.
Measurement of plasma leptin, insulin,
adiponectin, peptide YY (PYY) and monocyte
chemoattractant protein (MCP-1)
Plasma leptin, insulin, PYY, and MCP-1 were measured using
the mouse metabolic magnetic bead panel kit and adiponectin
was determined with the mouse single plex adiponectin kit
(Merck Millipore, MA, USA). The homeostasis model assess-
ment (HOMA) of insulin sensitivity was calculated using the
following formula: (fasting glucose [mmol/l] multiplied by fast-
ing insulin [U/ml] divided by 22.5) (21).
Histological analysis and morphometry
Epididymal adipose tissue was fixed in 10% buffered form-
aldehyde and embedded in paraffin. Tissue sections (5 m) were
cut and mounted onto polysine slides. The sections were stained
with hematoxylin and eosin and photographed at 100 magni-
fication. Using the software Image J 1.46r (http://rsbweb.nih-
.gov/ij/download.html) two fields per section and six sections per
fat mass were analyzed to quantify the area and number of
adipocytes.
Western blot analysis
As described in our previous study (22), for protein extraction
the frozen tissues were homogenized in a NP-40 lysis buffer. The
following antibodies were used: TNF- (sc-8301), IL-1 (sc-
7884) and IL-6 (sc-7920) from Santa Cruz Biotechnology, and
p-IKK (Ser176/180) (#2697), p-IB (Ser32) (#2859), p-STAT3
(Tyr705) (#9145) and SOCS3 (#2932) from Cell Signaling Tech-
nology (Beverly, MA). The bands corresponding to the proteins
of interest were scanned and band density analyzed using the
automatic imaging analysis system, Quantity One (BioRad). All
quantitative analyses were normalized to -actin, based on our
previous studies (22). Due to the small amount of tissue in the
mediobasal hypothalamus, we used a previously described mod-
ified multistrip western blot (23), which allows the detection of
multiple proteins with a smaller sample size than standard west-
ern blot (see supplementary figure 1 for details).
qPCR for neuropeptide mRNA measurement
Total mediobasal hypothalamic RNA was extracted using the
Aurum total RNA mini kit (Bio-Rad Laboratories, Hercules,
CA) and reverse-transcribed to first-strand complementary
DNA (cDNA) with the high-capacity cDNA reverse transcrip-
tion kit (AB Applied Biosystems, California, USA) according to
the manufacturer’s instructions. Quantitative real-time PCR
(qPCR) was performed in a 20 l final reaction volume using
SYBR green I master in a Lightcycler 480 (F. Hoffmann-La
Roche Ltd, Switzerland). Primers used are listed in supplemental
Table 1. Amplification was carried out with 45 cycles of 95°C for
10 s, 60°C for 30 s and 72°C for 30 s. mRNA expression levels
for neuropeptides were normalized to gamma actin, which
served as the internal control. Experiments were performed in
triplicate. The level of expression for each gene was calculated
using the comparative threshold cycle value (Ct) method, using
the formula 2–Ct (where Ct Ct sample - Ct reference)
as described previously (24, 25).
Statistical analysis
Data were analyzed using the SPSS 19 statistical package
(SPSS, Chicago, IL, USA). Two-way repeated-measure ANOVA
followed by two-tailed student’s t-tests were used to analyze
body weight and food intake during the teasaponin treatment.
Two-tailed student’s t-tests were used to analyze adipose tissue
histology and weight, and liver weight between the teasaponin
treatment and vehicle groups. One-way analysis of variance
(ANOVA) followed by the post hoc Tukey–Kramer honestly
significant difference (HSD) test was used to analyze the condi-
tioned taste aversion assessment, plasma cytokines, hypotha-
lamic neuropeptides and central leptin sensitivity test. A p value
of less than 0.05 was regarded as statistically significant, and p
values of less than 0.10 were considered a trend. Values are
expressed as mean  SEM.
Results
Teasaponin reduced body weight and food intake
in obese mice
When teasaponin was administrated via ip injection to
HF diet-induced obese mice it significantly reduced body
weight and food intake during the 21-d observation period
(Figures 1A and 1B). The body weight and food intake
during the teasaponin treatment were significantly af-
fected by the treatment, week factors and their interaction
(supplementary Table 2). The final body weight and av-
erage energy intake of the teasaponin group was also sig-
nificantly lower than the HF control group following
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treatment (final body weight: –11.05%, P  .004; average
energy intake: –24%, P  .001, Figures 1A and 1C).
Reduction of food intake induced by teasaponin
was not associated with taste aversion
To determine whether the teasaponin induced reduc-
tion in food intake was due to taste aversion, a conditioned
taste aversion test was conducted. Mice injected with LiCl
consumed significantly less saccharin than the saline con-
trols (P  .001). In contrast, the mice that received an ip
injection of teasaponin had a comparable preference for
saccharin as the saline controls on the test day (Figure 1E),
indicating that malaise was not a factor in the suppressive
effect of teasaponin on food intake.
Teasaponin reduced body fat and inflammation in
adipose tissue of obese mice
Consistent with reduced body weight, teasaponin also
significantly reduced body fat in HF diet-induced obese
mice compared with the control group (Figure 2A). Com-
pared to the controls, teasaponin treated mice had signif-
icantly lower amounts of visceral and inguinal fat as a
percentage of body weight (Figure 2B). To determine
whether there was a region specific fat loss, selected fat
deposits were excised and weighed. The teasaponin treat-
ment significantly decreased visceral fat, including epidid-
ymal, mesenteric and perirenal fat deposits compared with
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Figure 1. Chronic administration of teasaponin (TS, 10 mg/kg ip for
21 d) significantly decreased body weight (A), daily food intake (B) and
average energy intake (C) in obese mice (n  16) fed a high-fat (HF)
diet for 16 wk. *P  .05 vs. HF control group. Panel D: Conditioned
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not teasaponin (10 mg/kg ip) caused a conditioned taste aversion
assessment in mice. Values are expressed as mean  SEM, n  8.
**P  .001 vs. saline controls.
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the saline controls (Table 1, Figure 2C). Teasaponin af-
fected the size of adipocytes, with adipocytes from visceral
fat pads being significantly smaller in teasaponin-treated
HF diet-induced mice than in the HF
controls (Figures 2D and 2E). The
distribution of adipocytes by cell sur-
face area also showed a higher pro-
portion of small sized cells (1000
m2) in the teasaponin-treated HF
group than the HF control group
(Figure 2F). Finally, we found that
the teasaponin treatment signifi-
cantly reduced the protein levels of
the proinflammatory cytokines
(TNF- and IL-1), as well as the in-
flammatory signaling molecules (p-
IKK and p-IB), in the adipose tis-
sue of HF diet-induced obese mice
(Figure 2G).
Teasaponin significantly
decreased hepatic inflammation
Upon gross examination we
found that the teasaponin treated liv-
ers weighed less and were visibly less
steatotic than the livers from the con-
trol HF diet-induced obese mice (Fig-
ures 3A and 3B). Teasaponin signif-
icantly reduced the expression of
hepatic TNF-, IL-6, p-IKK and
p-IB protein in the HF diet-induced obese mice. How-
ever, teasaponin did not significantly affect the expression
of hepatic IL-1 and SOCS3 in the same animals (Figure
3C).
Teasaponin improved glucose tolerance and blood
hormone profiles
Glucose tolerance tests were performed to assess glu-
cose homeostasis and insulin sensitivity in HF diet-in-
duced obese mice treated with teasaponin. Blood glucose
levels were lower at the 30 and 60 min time points in the
teasaponin treatment group compared to the HF controls
during the glucose tolerance test (Figure 4A). The teasa-
ponin treatment also decreased HOMA (Figure 4B), in-
dicating that it reduced insulin resistance in the HF diet-
induced obese mice. HF diet-induced hyperinsulinemia
and hyperleptinemia were significantly reversed by teasa-
ponin treatment (Figures 4C and 4D). In a statistical trend,
teasaponin also reduced hypoadiponectinemia in mice in-
duced by the HF diet (P  .076) (Figure 4E). Circulating
concentrations of the satiety peptide PYY significantly in-
creased in the teasaponin treatment group compared with
the HF and LF mice (Figure 4F). There was no significant
difference in the plasma MCP-1 among the LF, HF and
teasaponin-treated HF groups (Figure 4G).
Table 1. Weight of fat deposits and muscle in high-fat
(HF) diet-induced obese mice with or without teasaponin
(TS) treatment.
Weight HF HFTS
F
value P value
Epididymal fat (g) 1.90

0.10
1.01

0.06
51.650 0.001
Mesenteric fat (g) 0.83

0.06
0.45

0.03
30.922 0.001
Perirenal fat (g) 0.75

0.07
0.28

0.03
32.323 0.001
Visceral fat (g) 3.49

0.22
1.69

0.10
50.678 0.001
Inguinal fat (g) 1.28

0.12
0.49

0.03
40.275 0.001
Soleus muscle
(mg)
21.31

0.77
19.50

0.60
3.449 0.072
Values are means SEM
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Figure 3. Effect of chronic administration of teasaponin on liver appearance (A) and liver weight
(B) and inflammatory markers (C) in the liver of obese mice (n  8) fed a high-fat (HF) diet for 16
wk. Panel C: In the liver, chronic treatment of teasaponin significantly decreased the protein
levels of the proinflammatory cytokines TNF- and IL-6, as well as the inflammatory signaling
molecules p-IKK and p-IB in HF-induced obese mice. *P  .05 vs. HF diet control group.
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Teasaponin increased the hypothalamic POMC
mRNA expression in obese mice
The effect of teasaponin on the expression of neuro-
peptides in the mediobasal hypothalamus was assessed to
investigate the mechanism by which teasaponin sup-
presses food intake. Chronic teasaponin treatment signif-
icantly increased hypothalamic anorexigenic POMC
mRNA expression compared to the HF control mice (P 
.026; Figure 5), but had no effect on orexigenic NPY and
AgRP mRNA levels.
Teasaponin attenuated
hypothalamic inflammation and
improved central leptin
sensitivity and leptin signaling
Western blot analysis showed
that in the mediobasal hypothala-
mus, a HF diet elevated TNF-, IL-6,
p-IKK and SOCS3 protein expres-
sion, which was significantly de-
creased by treatment with teasapo-
nin (Figure 6). We also evaluated if
leptin signaling in the CNS improved
in conjunction with the observed re-
duction in hypothalamic inflamma-
tion. Central leptin sensitivity was
examined at two stages of the obesity
model, after 8 and 16 wk of HF diet,
with acute and chronic teasaponin
treatment respectively. After 8 wk of
feeding leptin administered icv sig-
nificantly decreased energy intake
for 24 h in LF diet fed mice (-40%,
P  .001; Figure 7A), but not in HF
diet fed animals (-16%, P  .421;
Figure 7B). In contrast energy intake
was significantly decreased in the HF
diet fed and teasaponin-treated mice
receiving icv injections of leptin com-
pared with the icv saline control
(-46%, P  .014; Figure 7B).
Chronic treatment with teasaponin
also improved central leptin sensitiv-
ity in mice after 16 wk of high-fat
diet. Icv leptin injections did not sig-
nificantly suppress energy intake in
HF-induced obese mice without
teasaponin treatment (P  .633; Fig-
ure 7C), while energy intake was sig-
nificantly decreased in the teasapo-
nin-treated mice receiving icv
injections of leptin compared with
the icv injection of saline (-39%, P  .023; Figure 7C).
To clarify the mechanisms underlying the enhanced ef-
fect of leptin in the teasaponin-treated mice, we measured
p-STAT3 protein levels in the mediobasal hypothalamus
after the chronic treatment with teasaponin and leptin
stimulation. Leptin administered icv significantly in-
creasedp-STAT3 inLFdiet fedmice (P .001;Figure7D),
while p-STAT3 did not significantly increase in response
to the leptin injection in control HF diet-induced obese
mice (Figure 7E). With the teasaponin treatment, the p-
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STAT3 level significantly increased after icv leptin injec-
tion compared with icv saline (94%, P  .001) (Figure 7E).
Discussion
This study demonstrated that teasaponin treatment re-
duced obesity, peripheral and hypothalamic inflamma-
tion, and central leptin resistance in high-fat (HF) diet-
induced obese mice. Compared with the control obese
mice, the teasaponin treated obese mice had lower proin-
flammatory cytokines and signaling molecules in their vis-
ceral fat and liver. The anti-inflammatory effects of teasa-
ponin were associated with an improved glycemic status in
the treated animals, evidenced by improved glucose tol-
erance, HOMA and fasting plasma insulin. Furthermore,
teasaponin decreased proinflammatory cytokines and in-
flammatory signaling in the mediobasal hypothalamus,
and enhanced the anorexigenic effect of central leptin ad-
ministration as demonstrated by the restoration of
p-STAT3 signaling in the mediobasal hypothalamus.
Chronic teasaponin treatment also suppressed energy in-
take and increased the expression of the anorexigenic neu-
ropeptide POMC in the hypothalamus.
A low-grade proinflammatory state is at the pathogenic
core of obesity and its associated metabolic syndrome. We
have demonstrated for the first time that teasaponin (ip
injection) lowers proinflammatory cytokines (TNF-,
IL-6 and IL-1) in the adipose tissue of HF diet-induced
obese mice. Adiponectin is secreted from adipose tissue
and functions to reduce plasma glucose and fatty acid lev-
els (26). Several studies have shown that obesity-associ-
ated inflammation can impair the production of adiponec-
tin. For example, in vitro studies demonstrated that
TNF- and/or IL-1 suppressed adiponectin expression in
human preadipocytes, adipose tissue and the 3T3-L1 cell
line (27–29). In a human study, it was found that adi-
ponectin plasma levels and adipose-tissue gene expression
were significantly lower in obese subjects, and inversely
correlated with the inflammatory markers, IL-6 and high-
sensitive C-reactive protein (CRP) (30). In our study, the
teasaponin treatment was found to increase the level of
plasma adiponectin in HF mice, which may result from the
inhibition of the proinflammatory cytokine expression in
abdominal fat. The increase of plasma adiponectin after
teasaponin treatment may contribute to the antidiabeto-
genic effect observed in this study, as treatment with adi-
ponectin has been found to improve insulin sensitivity in
obese mice (31).
The inflammatory signaling molecules p-IKK and
p-IB were decreased in the adipose tissue and liver of
obese mice treated with teasaponin. The IKK/IB com-
plex mediates the activity of the NF-B transcription fac-
tor to regulate the expression of various cytokines. Acti-
vation of IKK by phosphorylation induces
phosphorylation and degradation of its substrate, the in-
hibitory protein IB, which is normally bound to NFB.
The dissociation and degradation of IB releases NFB
to translocate into the nucleus and mediate the transcrip-
tion of various genes, including TNF-, IL-1 and IL-6
(32). Mice overexpressing IKK in their hepatocytes had an
increased hepatic production of IL-6, IL-1 and TNF-
(6). We have shown that teasaponin reduces the phos-
phorylation of IKK and IB in the liver and adipose tis-
sue, indicating that teasaponin inhibits proinflammatory
cytokines by suppressing NFB signaling upstream of
IKK/IB. The NF-B signaling pathway affects glucose
metabolism in multiple tissues (6, 33). For example, mice
overexpressing IKK in hepatocytes exhibit hyperglycemia,
profound hepatic insulin resistance and moderate sys-
temic insulin resistance (6). Recently, IKK has been iden-
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tified as a target of anti-inflammatory therapy for the
treatment of obesity-associated type 2 diabetes. Hepato-
cyte-specific deletion of IKK improved insulin sensitivity
in mice fed a HF diet (33). The pharmacological inhibition
of IKK also prevented liver steatosis in obese mice (34).
Thus, teasaponin represents a novel strategy to suppress
IKK/IB complex mediated responses, and ameliorate
the metabolic disorders related to diet-induced obesity.
Dietary teasaponin supplementation (0.5%) for 11 wk
prevented fat accumulation and obesity in mice fed a high-
fat diet by inhibiting pancreatic lipase activity, thereby
delaying the intestinal absorption of dietary fat (35). In the
current study, the chronic ip administration of teasaponin
decreased body weight and improved many other obesity-
linked parameters in mice after fed a HF diet for 16 wk.
Furthermore, ip injection of teasaponin suppressed food
intake in the obese mice, consistent with a previous study
where the oral administration of teasaponin decreased the
short-term feeding response in chicks (36). In addition, we
found that suppressing food intake did not elicit malaise,
in that an effective dose (ED) of
teasaponin did not cause a condi-
tioned taste aversion. Therefore, vis-
ceral illness is unlikely to be a factor
in the feeding suppressive actions of
peripherally administered teasapo-
nin. Importantly, this study found
that teasaponin treatment increased
the satiety hormone peptide YY
(PYY) in the plasma of HF diet-in-
duced obese mice. Peripheral infu-
sion of PYY reduces food intake in
rodents (37), and PYY transgenic
mice with increased plasma PYY
concentrations are protected against
diet-induced obesity (38). In this
study, the teasaponin induced in-
crease in plasma PYY may contrib-
ute to the suppression of food intake
and decrease in body weight in HF
diet-induced obese mice. The precise
mechanism by which teasaponin el-
evated the plasma concentrations of
PYY is unclear, however it is known
that PYY is released from specialized
enteroendocrine cells called L cells,
predominantly located in the mu-
cosa of the distal gastrointestinal
(GI) tract (39). A HF diet induces ox-
idative GI mucosal injury in rats
(40), and teasaponin has previously
been shown to have gastroprotective
effects, where the oral administration of teasaponin pre-
vented the gastric lesions induced by ethanol in rats (41).
Therefore, the prevention of gastric lesions by teasaponin
may increase the PYY secretion in the GI tract of HF diet-
induced obese mice.
Two types of neurons regulate energy balance in the Arc
of the mediobasal hypothalamus, anorexigenic (POMC)
and orexigenic (NPY/AgRP). Chronic teasaponin treat-
ment significantly increased POMC, but not NPY/AgRP
mRNA in the hypothalamic Arc of HF diet-induced obese
mice, implying that teasaponin exerts its anorexigenic ac-
tion at least partially by activating the POMC system. It
has been reported that peripheral PYY activates anorex-
igenic POMC neurons in the hypothalamic Arc. Intraperi-
toneal injection of the truncated form of PYY (PYY3–36)
increased the expression of c-fos in the POMC neurons
(42, 43), expression of POMC mRNA (44), and the action
potential firing rate of POMC neurons in the hypotha-
lamic Arc (42). Therefore, the teasaponin-induced in-
crease in POMC mRNA expression may result from ele-
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vated plasma PYY levels. However, Ghamari-Langroudi
et al. reported that in an electrophysiological slice study,
PYY3–36 inhibited the action potential firing activity of
POMC neurons of the arcuate nucleus through the post-
synaptic Y2 receptor (45). Therefore, the role of POMC
neurons in mediating the anorexigenic response to periph-
eral PYY during teasaponin treatment requires further
study.
Leptin promotes negative energy balance by signaling
in the brain, and the hypothalamus is a key region for the
control of food intake by this hormone. This negative feed-
back loop becomes disrupted in most obese individuals,
resulting in a state known as central leptin resistance. In
this study we confirmed central leptin resistance in HF diet
induced obese mice. The icv injection of leptin signifi-
cantly decreased food intake in LF control mice, but not in
HF obese mice with hyperleptinemia. There are two mech-
anisms that explain central leptin resistance, hyperleptine-
mia (46) and hypothalamic inflammation (2, 47). Firstly,
it is reported that hyperleptinemia is required for the de-
velopment of leptin resistance in diet-induced obese mice
(46). In the current study, teasaponin significantly reduced
body fat and dramatically amelio-
rated hyperleptinemia induced by
HF diet-induced obesity. This may
have reduced the overstimulation of
the leptin receptor and downstream
signaling, thus improving central
leptin sensitivity. Secondly, recent
studies have revealed that hypotha-
lamic inflammation can mediate cen-
tral leptin resistance in HF diet-in-
duced obese rodents (2, 47).
Constitutive activation of IKK in
the hypothalamus of mice induced
central leptin resistance and im-
paired leptin signaling through
p-STAT3 (47). In contrast, a genetic
or pharmacological blockade of in-
flammatory signaling in the hypo-
thalamus improved leptin sensitivity
and elevated p-STAT3 (47, 48). In
mice with an IKK knockout in hypo-
thalamic AgRP neurons, the level of
p-STAT3 was significantly increased
in response to icv administered leptin
in animals fed a HF diet (47). In this
study, teasaponin decreased the ex-
pression of the hypothalamic proin-
flammatory cytokines and inflam-
matory signaling molecules, such as
TNF-, IL-6, IL-1 and p-IKK. This
may have contributed to the improved leptin sensitivity
and hypothalamic leptin signaling via p-STAT3 following
the teasaponin treatment in the diet-induced obese mice.
SOCS3 has been identified as a negative regulator of
central leptin signaling. The overexpression of SOCS-3
results in the inhibition of leptin signaling through JAK2/
STAT3 (49). Negative feedback in response to excessive
hormone stimulation is a classical mechanism of hormone
resistance. It is known that leptin stimulates the expression
of SOCS3, which directly inhibits leptin signaling in the
hypothalamus (50). Furthermore, overexpression of IKK
in the hypothalamic neurons of mice increases SOCS3
mRNA expression and protein levels in the hypothalamus
(47). Therefore in the current study, hyperleptinemia and
hypothalamic inflammation in diet-induced obese mice
may activate a common negative regulator of leptin sig-
naling, SOCS3, and contribute to central leptin resistance.
Upregulation of SOCS3 in POMC neurons leads to im-
pairment of STAT3 signaling, with subsequent leptin re-
sistance, obesity, and glucose intolerance (51). In contrast,
hypothalamic SOCS3-deficient rats exhibited enhanced
leptin-induced STAT3 activation, decreased body weight
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gain and improved metabolic parameters when exposed to
a high-fat diet (52). In the present study, teasaponin sig-
nificantly decreased the level of SOCS3 in the hypothal-
amus of HF induced obese mice, suggesting that SOCS3 is
a potential target for teasaponin’s therapeutic interven-
tion during obesity.
In summary, we have demonstrated that chronic teasa-
ponin treatment significantly reduced food intake and
body weight in HF diet-induced obese mice. Teasaponin
also increased the circulating concentrations of the an-
orexigenic hormone PYY, and stimulated the expression
of the hypothalamic neuropeptide POMC. Treatment
with teasaponin significantly ameliorated peripheral and
central inflammation by reducing proinflammatory cyto-
kines and inflammatory signaling molecules in the liver,
adipose tissue and hypothalamus. Therefore, teasaponin
has important effects in improving glucose tolerance, cen-
tral leptin sensitivity and hypothalamic leptin signaling.
These results identify a novel role for teasaponin as an
antiobesity and anti-inflammatory agent.
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